
Celebrating World Adherence Day at Servier Philippines!
31/03/2025
 thousand employees
countries in which the Group’s
 medicines are distributed 20%
of revenue from brand-name
 medicines invested in R&D
 each year
euros in revenue in 2023/2024 including
 €4.5 billion for brand-name medicines
 and €1.4 billion for generic activities
Oncology, Cardiometabolism &
 Venous Diseases, Neurology